Cargando…

Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report

The anti-CV2/CRMP5 antibody is a well-characterized biomarker of paraneoplastic neurological syndrome. The anti-NF186 antibody is a recently discovered antibody associated with central or peripheral demyelination. The co-occurrence of these two antibodies has not been reported. Herein, we report a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Bingyou, Zhou, Lei, Zheng, Yongsheng, Sun, Chong, Lin, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046875/
https://www.ncbi.nlm.nih.gov/pubmed/36979184
http://dx.doi.org/10.3390/brainsci13030374
_version_ 1785013781821128704
author Liu, Bingyou
Zhou, Lei
Zheng, Yongsheng
Sun, Chong
Lin, Jie
author_facet Liu, Bingyou
Zhou, Lei
Zheng, Yongsheng
Sun, Chong
Lin, Jie
author_sort Liu, Bingyou
collection PubMed
description The anti-CV2/CRMP5 antibody is a well-characterized biomarker of paraneoplastic neurological syndrome. The anti-NF186 antibody is a recently discovered antibody associated with central or peripheral demyelination. The co-occurrence of these two antibodies has not been reported. Herein, we report a case with anti-CV2/CRMP5 and anti-NF186 antibodies in a 57-year-old male presenting with progressive numbness and weakness in his four limbs. At first admission, the spinal cord MRI showed a cervical cord demyelinating lesion and electrophysiological examination showed a mixed demyelinating and axonal polyneuropathy. Anti-CV2/CRMP5 and anti-NF186 antibodies were both detected in his serum. Initially, the patient showed a positive response to IVIG and glucocorticoid treatment. However, the syndrome relapsed and mass lesions in lung and mediastinum were detected at second admission. This time the anti-NF186 antibody was not detected but the anti-CV2/CRMP5 antibody was still present. IVIG and glucocorticoid treatment was no longer effective. This case illustrated that paraneoplastic syndrome should be considered when diagnosing patients with central and peripheral demyelination, and that the anti-NF186 antibody may help distinguish a subset of patients who can benefit from immunomodulatory treatments.
format Online
Article
Text
id pubmed-10046875
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100468752023-03-29 Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report Liu, Bingyou Zhou, Lei Zheng, Yongsheng Sun, Chong Lin, Jie Brain Sci Case Report The anti-CV2/CRMP5 antibody is a well-characterized biomarker of paraneoplastic neurological syndrome. The anti-NF186 antibody is a recently discovered antibody associated with central or peripheral demyelination. The co-occurrence of these two antibodies has not been reported. Herein, we report a case with anti-CV2/CRMP5 and anti-NF186 antibodies in a 57-year-old male presenting with progressive numbness and weakness in his four limbs. At first admission, the spinal cord MRI showed a cervical cord demyelinating lesion and electrophysiological examination showed a mixed demyelinating and axonal polyneuropathy. Anti-CV2/CRMP5 and anti-NF186 antibodies were both detected in his serum. Initially, the patient showed a positive response to IVIG and glucocorticoid treatment. However, the syndrome relapsed and mass lesions in lung and mediastinum were detected at second admission. This time the anti-NF186 antibody was not detected but the anti-CV2/CRMP5 antibody was still present. IVIG and glucocorticoid treatment was no longer effective. This case illustrated that paraneoplastic syndrome should be considered when diagnosing patients with central and peripheral demyelination, and that the anti-NF186 antibody may help distinguish a subset of patients who can benefit from immunomodulatory treatments. MDPI 2023-02-21 /pmc/articles/PMC10046875/ /pubmed/36979184 http://dx.doi.org/10.3390/brainsci13030374 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Liu, Bingyou
Zhou, Lei
Zheng, Yongsheng
Sun, Chong
Lin, Jie
Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report
title Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report
title_full Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report
title_fullStr Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report
title_full_unstemmed Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report
title_short Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report
title_sort paraneoplastic syndrome presenting combined central and peripheral demyelination associated with anti-cv2/crmp5 and anti-nf186 antibodies: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046875/
https://www.ncbi.nlm.nih.gov/pubmed/36979184
http://dx.doi.org/10.3390/brainsci13030374
work_keys_str_mv AT liubingyou paraneoplasticsyndromepresentingcombinedcentralandperipheraldemyelinationassociatedwithanticv2crmp5andantinf186antibodiesacasereport
AT zhoulei paraneoplasticsyndromepresentingcombinedcentralandperipheraldemyelinationassociatedwithanticv2crmp5andantinf186antibodiesacasereport
AT zhengyongsheng paraneoplasticsyndromepresentingcombinedcentralandperipheraldemyelinationassociatedwithanticv2crmp5andantinf186antibodiesacasereport
AT sunchong paraneoplasticsyndromepresentingcombinedcentralandperipheraldemyelinationassociatedwithanticv2crmp5andantinf186antibodiesacasereport
AT linjie paraneoplasticsyndromepresentingcombinedcentralandperipheraldemyelinationassociatedwithanticv2crmp5andantinf186antibodiesacasereport